Is GILD a good stock to buy? We came across a bullish thesis on Gilead Sciences, Inc. on r/investing_discussion by Variant_Invest. In this article, we will summarize the bulls’ thesis on GILD. Gilead Sciences, Inc.’s share was trading at $133.73 as of May 26th. GILD’s trailing and forward P/E were 18.19 and 15.22 respectively according to Yahoo Finance.
Pressmaster/Shutterstock.com
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States and internationally. GILD is being mischaracterized by the market as a slow-growth HIV cash cow despite a rapidly shifting pipeline that increasingly skews toward long-acting HIV innovation and a credible oncology expansion, suggesting the current valuation underappreciates its multi-platform earnings durability.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
The HIV franchise is not in structural decline but is transitioning through lenacapavir, a twice-yearly injectable for treatment and prevention, with PURPOSE 1 and PURPOSE 2 trials demonstrating 100% and 96% efficacy, positioning it as a potential paradigm shift in adherence and prevention economics. Oncology provides the second pillar with Trodelvy showing traction in triple-negative breast cancer and additional bladder cancer expansion, while broader pipeline assets, despite prior setbacks like magrolimab, still create meaningful optionality that is currently priced near zero by the market.
With over 17 billion dollars in operating cash flow and a fortress balance sheet, Gilead can fund long-duration pipeline development without financial strain, supporting sustained R&D investment while maintaining a 3.5% dividend yield that anchors downside risk. At 10–11x forward earnings, the stock trades at a discount to typical pharmaceutical peers and even utility-like companies, implying the market is not pricing in successful execution of either HIV innovation or oncology optionality.
If either lenacapavir adoption accelerates or oncology assets achieve commercial success, rerating potential becomes significant given the current compressed multiple and resilient cash generation base. Overall, the setup reflects asymmetric upside with limited downside given cash flows, while consensus underestimates the speed and magnitude of the HIV transition and oncology monetization trajectory over time materially.
Previously, we covered a bullish thesis on Gilead Sciences, Inc. (GILD) by Disruptive analytics in February 2025, which highlighted near-term revenue headwinds from policy, FX, and COVID normalization limiting upside despite cost discipline. GILD’s stock price has appreciated by approximately 28.48% since our coverage. Variant_Invest shares a similar view but emphasizes pipeline-driven re-rating from lenacapavir and oncology optionalities growth.
Gilead Sciences, Inc. is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 77 hedge fund portfolios held GILD at the end of the first quarter which was 71 in the previous quarter. While we acknowledge the risk and potential of GILD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than GILD and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
